Amitriptyline nanoparticle repositioning prolongs the anti-allodynic effect of enhanced microglia targeting
- PMID: 39229790
- PMCID: PMC11485917
- DOI: 10.1080/17435889.2024.2390349
Amitriptyline nanoparticle repositioning prolongs the anti-allodynic effect of enhanced microglia targeting
Abstract
Aim: Amitriptyline (AMI) has been used to treat neuropathic pain. However, the clinical outcomes remain unsatisfactory, presumably due to a limited understanding of the underlying molecular mechanisms. Here, we investigated a drug repositioning strategy using a low-dose of AMI encapsulated in poly (D, L lactic-co-glycolic acid) (PLGA) nanoparticles (AMI NPs) for neuropathic pain, since PLGA nanoparticles are known to enhance delivery to microglia.Methods: We evaluated the anti-allodynic effects of AMI and AMI NPs on neuropathic pain by assessing behaviors and inflammatory responses in a rat model of spinal nerve ligation (SNL). While the anti-allodynic effect of AMI (30 μg) drug injection on SNL-induced neuropathic pain persisted for 12 h, AMI NPs significantly alleviated mechanical allodynia for 3 days.Results: Histological and cytokine analyses showed AMI NPs facilitated the reduction of microglial activation and pro-inflammatory mediators in the spinal dorsal horn. This study suggests that AMI NPs can provide a sustained anti-allodynic effect by enhancing the targeting of microglia and regulating the release of pro-inflammatory cytokines from activated microglia.Conclusion: Our findings suggest that the use of microglial-targeted NPs continuously releasing AMI (2 μg) as a drug repositioning strategy offers long-term anti-allodynic effects.
Keywords: PLGA nanoparticles; amitriptyline; microglia; neuropathic pain.
Plain language summary
[Box: see text].
Conflict of interest statement
The authors have no competing interests or relevant affiliations with any organization or entity with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.
Similar articles
-
PLGA nanoparticle-mediated anti-inflammatory gene delivery for the treatment of neuropathic pain.Nanomedicine (Lond). 2025 May;20(9):943-954. doi: 10.1080/17435889.2025.2487410. Epub 2025 Apr 5. Nanomedicine (Lond). 2025. PMID: 40186589
-
Antidepressants for chronic non-cancer pain in children and adolescents.Cochrane Database Syst Rev. 2017 Aug 5;8(8):CD012535. doi: 10.1002/14651858.CD012535.pub2. Cochrane Database Syst Rev. 2017. PMID: 28779487 Free PMC article.
-
Phosphodiesterase 2A as a Therapeutic Target for Relieving Mechanical Allodynia and Modulating Microglial Polarization in Neuropathic Pain Models Following Spinal Cord Injury.ACS Chem Neurosci. 2025 Jul 16;16(14):2629-2638. doi: 10.1021/acschemneuro.5c00169. Epub 2025 Jun 28. ACS Chem Neurosci. 2025. PMID: 40580118
-
CX3CR1-Targeted PLGA Nanoparticles Reduce Microglia Activation and Pain Behavior in Rats with Spinal Nerve Ligation.Int J Mol Sci. 2020 May 14;21(10):3469. doi: 10.3390/ijms21103469. Int J Mol Sci. 2020. PMID: 32423102 Free PMC article.
-
Antiepileptic drugs for chronic non-cancer pain in children and adolescents.Cochrane Database Syst Rev. 2017 Aug 5;8(8):CD012536. doi: 10.1002/14651858.CD012536.pub2. Cochrane Database Syst Rev. 2017. PMID: 28779491 Free PMC article.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Miscellaneous